Department of Chemistry , University of Science & Technology of China , Hefei , Anhui 230026 , China.
Anal Chem. 2019 Mar 5;91(5):3652-3658. doi: 10.1021/acs.analchem.8b05696. Epub 2019 Feb 14.
As acute myocardial infarction (AMI) has now become a severe death threat to humans and may abruptly occur at home or outdoors where sophisticated equipment is not available, it is of great importance to develop facile methodologies for the point-of-care (POC) diagnosis of AMI. Toward this goal, here we build a sensing platform for chemiluminescence (CL) microRNA (miRNA) imaging with a smartphone as the portable detector, and for the first time we achieve visualization of AMI-related miRNAs in real patients' serum. We first construct a spherical nucleic acid enzyme (termed SNAzyme) derived from a dense layer of G-quadruplex (G4) DNAzyme formed on the gold nanoparticle core, which displays ∼100-fold and higher catalytic activity and improved resistance to nuclease degradation in a real blood sample as compared to those of the G4 DNAzyme itself. These unique features endow the SNAzyme-boosted CL platform with superior imaging performance for analyzing an AMI-related miRNA, miRNA-133a. This miRNA is employed to trigger the target-catalyzed hairpin assembly to produce a sticky dsDNA linker that captures the SNAzyme nanolabel onto the substrate. In this way, miRNA-133a is successfully detected, with a limit of detection of 0.3 pM (S/N = 3) and a high selectivity over other miRNA analogs in patients' blood. Given its unique features in physiological environments, our SNAzyme-boosted imaging platform holds great promise for use in the POC diagnosis of AMI.
由于急性心肌梗死(AMI)现在已成为对人类的严重死亡威胁,且可能在家中或户外等无法使用复杂设备的地方突然发生,因此开发用于即时护理(POC)诊断 AMI 的简便方法非常重要。为此,我们构建了一个基于智能手机的化学发光(CL)microRNA(miRNA)成像传感平台,首次实现了对真实患者血清中与 AMI 相关的 miRNA 的可视化。我们首先构建了一种球形核酸酶(称为 SNAzyme),它由金纳米颗粒核心上形成的密集层 G-四链体(G4)DNA 酶组成,与 G4 DNA 酶本身相比,在真实血液样本中显示出约 100 倍甚至更高的催化活性和对核酸酶降解的增强抗性。这些独特的特性赋予了 SNAzyme 增强的 CL 平台优越的成像性能,可用于分析与 AMI 相关的 miRNA,miRNA-133a。该 miRNA 用于触发靶标催化发夹组装,产生粘性 dsDNA 接头,将 SNAzyme 纳米标签捕获到基底上。通过这种方式,成功检测到 miRNA-133a,其检测限为 0.3 pM(S/N = 3),在患者血液中对其他 miRNA 类似物具有高选择性。鉴于其在生理环境中的独特特性,我们的 SNAzyme 增强的成像平台有望用于 AMI 的 POCT 诊断。